TLX

TRANS LUX CORPORATION

TLX

Overview Fund Activity

Delisted

TLX was delisted on the 16th of November, 2010.

Back to rankings

Industrials Specialty Industrial Machinery

Financial journalist opinion

TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Telix and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again – Hagens Berman

SAN FRANCISCO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- On August 28, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares fall about 16% after the company said the FDA sought more data on its drug to detect a form of kidney cancer.

Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again – Hagens Berman

Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX

NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd.

Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX

Telix Pharmaceuticals Limited (TLX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Telix Pharmaceuticals Limited (NASDAQ:TLX ) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 12:00 PM EDT Company Participants Christian Behrenbruch - Co-Founder, MD, Group CEO & Executive Director Conference Call Participants Robert Burns - H.C.

Telix Pharmaceuticals Limited (TLX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to include prostate cancer diagnosis.

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

Telix Pharmaceuticals Limited (TLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Telix Pharmaceuticals Limited (NASDAQ:TLX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:50 PM EDT Company Participants Christian Behrenbruch - Co-Founder, MD, Group CEO & Executive Director Conference Call Participants David Bailey - Morgan Stanley, Research Division Presentation David Bailey Equity Analyst Okay. Good afternoon, everyone.

Telix Pharmaceuticals Limited (TLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Sept. 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX

NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd.

Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

NEW YORK , Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

See News Rankings

Charts implemented using Lightweight Charts™